Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 69,300 KRW
Change Today -1,700.00 / -2.39%
Volume 614.8K
068270 On Other Exchanges
As of 2:29 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

celltrion inc (068270) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/14/15 - 97,400
52 Week Low
12/12/14 - 35,476
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLTRION INC (068270)

Related News

No related news articles were found.

celltrion inc (068270) Related Businessweek News

No Related Businessweek News Found

celltrion inc (068270) Details

Celltrion, Inc. researches, develops, manufactures, and sells biopharmaceutical products in South Korea and internationally. It develops and manufactures biosimilar monoclonal antibodies (mAbs) and therapeutics for oncology and autoimmune diseases. The company markets Remsima, a biosimilar mAb and tumor necrosis factor antagonist that is used to treat rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, plaque psoriasis, and psoriatic arthritis. Its product pipeline includes CT-P6 for the treatment of breast cancer; CT-P10 for the treatment of non- Hodgkin’s lymphoma and rheumatoid arthritis; and CT-P27, a therapeutic antibody for treatment against universal influenza, which has completed Phase IIA clinical trials. The company is also jointly developing mAbs for rabies with the Center for Disease Control and Prevention in the United States; antibodies against various virus subtypes and drug resistant hepatitis B viruses; Anti–GP88, mAbs for treatment of breast and lung cancer diseases; antibody-drug conjugate. In addition, it offers contract manufacturing services to biopharmaceutical companies. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Founded in 2002

celltrion inc (068270) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

celltrion inc (068270) Key Developments

Celltrion Receives Approval from ANVISA for Remsima

Celltrion has received approval from ANVISA, the National Health Surveillance Agency in Brazil for Remsima (infliximab), the first biosimilar monoclonal antibody approved for use in Brazil. The medication will be marketed by Hospira. Hospira also markets and sells biosimilar infliximab in 26 European countries and in Canada under the brand name Inflectra. This important product has been approved in Brazil for the treatment of: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn's disease in adults and children, fistulizing Crohn's disease (advanced), colitis and ulcerative rectocolitis. Remsima is the first biological medication approved by Brazil's regulator, ANVISA, based on comparability. A comparability study is required because under ANVISA's Normative Resolution RDC 55/2010, biosimilarity must be proven by direct comparison with the reference biological drug.

Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2014

Celltrion, Inc. reported earnings results for the full year ended December 31, 2014. For the period, the company reported sales of KRW 404,621,867,934, operating income of KRW 195,764,018,071, income from continuing operations before income tax of KRW 162,201,484,097, income from continuing operation and net income of KRW 128,060,383,547 against sales of KRW 224,575,287,050, operating income of KRW 100,983,544,044, income from continuing operations before income tax of KRW 116,766,418,113, income from continuing operation and net income of KRW 103,754,409,098 a year ago.

Celltrion, Inc., Annual General Meeting, Mar 20, 2015

Celltrion, Inc., Annual General Meeting, Mar 20, 2015., at 10:00 Korea Standard Time. Location: Songdo Convensia Yeonsugu songdodong 6-1 second floor meeting room. Agenda: To consider approval of financial statements based on the second bill; to consider appointment of inside directors; to consider appointment of Audit Committee; to consider approval of director remuneration bill; and to consider approval of stock option grant.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
068270:KS 69,300.00 KRW -1,700.00

068270 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 068270.
View Industry Companies

Industry Analysis


Industry Average

Valuation 068270 Industry Range
Price/Earnings 98.5x
Price/Sales 15.6x
Price/Book 4.8x
Price/Cash Flow 100.1x
TEV/Sales 13.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLTRION INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at